ArticleGeroScience2026
Bidirectional associations between biological aging, cardiovascular health, and cardiovascular risk: findings from the INSPIRE-T lifespan cohort.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Chronological age is a common and non-modifiable factor for chronic disease, but does not fully explain age-related changes. Biological clocks have been developed to explore biological aging mechanisms. They could help identify protective factors against accelerated aging and associated diseases. We aim to assess the association between reduced epigenetic or inflammatory aging and ideal cardiovascular health or cardiovascular risk. We conducted a cross-sectional analysis of participants from the INSPIRE-T cohort. Cardiovascular health (CVH) was assessed using the Life's Essential 8 score. Cardiovascular risk was assessed using the American Framingham risk score (FRS) and the European Systematic Coronary Risk Evaluation (SCORE2) score. Epigenetic and inflammatory aging was calculated from the residuals from linear regression of biological age (based on five epigenetic clocks and one inflammatory clock) and chronological age. Linear and logistic regression models were used. Better CVH has been associated with slower epigenetic aging, particularly in younger subjects and men. Accelerated epigenetic aging measured by GrimAge was associated with an increase cardiovascular risk (for SCORE2: OR = 1.10 95%CI [1.04; 1.16]). No persistent association was found with the inflammatory clock. Our study reported an association between ideal global CVH with reduced epigenetic aging after adjustment for chronological age and gender. This suggests that epigenetic aging may be modifiable through healthy lifestyle and cardiovascular risk management, although a potential underlying causal relationship remains to be established. Moreover, accelerated epigenetic aging is linked to worsening cardiovascular risk, and could be a new risk factor alongside chronological age.
Indexed as
Identifiers
41979831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.